Opinion|Videos|April 4, 2025

Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation

Panelists discuss how to optimize treatment outcomes by managing the transition from biologics to JAK inhibitors and considering dose adjustment strategies when patients show inadequate response to initial therapy.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME